A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients
M-K Chuang1, Y-C Chiu2, W-C Chou3
1Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract:
As a highly heterogeneous disease, acute myeloid leukemia (AML) needs fine risk stratification to get an optimal outcome of patients. MicroRNAs have florid biological functions and have critical roles in the pathogenesis and prognosis in AML. Expression levels of some single microRNAs are influential for prognosis, but a system integrating several together and considering the weight of each should be more powerful. We thus analyzed the clinical, genetic and microRNA profiling data of 138 de novo AML patients of our institute. By multivariate analysis, we identified that high expression of hsa-miR-9-5p and hsa-miR-155-5p were independent poor prognostic factors, whereas that of hsa-miR-203 had a trend to be a favorable factor. We constructed a scoring system from expression of these three microRNAs by considering the weight of each. The scores correlated with distinct clinical and biological features and outperformed single microRNA expression in prognostication. In both ours and another validation cohort, higher scores were associated with shorter overall survival, independent of other well-known prognostic factors. By analyzing the mRNA expression profiles, we sorted out several cancer-related pathways highly correlated with the microRNA prognostic signature. We conclude that this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients.
Insights
A new scoring system using three microRNAs (hsa-miR-9-5p, hsa-miR-155-5p, and hsa-miR-203) effectively stratifies risk in acute myeloid leukemia (AML) patients. This system improves prognostic accuracy for better patient outcomes.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous cancer requiring precise risk stratification for optimal patient management.
- MicroRNAs play crucial roles in AML pathogenesis and prognosis, with individual microRNAs showing prognostic influence.
- Integrating multiple microRNAs with weighted analysis offers a potentially more powerful prognostic tool.
Purpose of the Study:
- To develop and validate a novel microRNA-based scoring system for risk stratification in de novo AML patients.
- To identify specific microRNAs (hsa-miR-9-5p, hsa-miR-155-5p, hsa-miR-203) as prognostic factors in AML.
- To correlate the microRNA scoring system with clinical features, biological characteristics, and patient survival.
Main Methods:
- Analysis of clinical, genetic, and microRNA profiling data from 138 de novo AML patients.
- Multivariate analysis to identify independent prognostic microRNAs.
- Construction of a weighted 3-microRNA scoring system.
- Validation of the scoring system in an independent patient cohort.
- Correlation analysis with mRNA expression profiles and cancer-related pathways.
Main Results:
- High expression of hsa-miR-9-5p and hsa-miR-155-5p were identified as independent poor prognostic factors in AML.
- High expression of hsa-miR-203 showed a trend towards a favorable prognostic factor.
- The 3-microRNA scoring system demonstrated superior prognostication compared to single microRNA expression.
- Higher scores were significantly associated with shorter overall survival, independent of other known prognostic factors.
- The microRNA signature correlated with specific cancer-related pathways.
Conclusions:
- A simple and powerful 3-microRNA scoring system (hsa-miR-9-5p, hsa-miR-155-5p, hsa-miR-203) enables effective risk stratification for de novo AML patients.
- This scoring system improves prognostic accuracy and can aid in optimizing patient management strategies.
- The findings highlight the potential of integrated microRNA analysis in understanding AML complexity and improving outcomes.
